The US Food and Drug Administration (FDA) has announced the recall of 135 batches of potassium chloride extended-release capsules due to potential risks of cardiac arrest. 

FDA Announces Recall of 114 Batches of Glenmark Pharmaceuticals Capsules Over Cardiac Arrest Fear

According to The New York Post, Glenmark Pharmaceuticals recalled 114 batches, while American Health Packaging, representing BluePoint Laboratories, recalled 21 batches. This voluntary recall stemmed from the capsules' failure to dissolve properly, which may lead to high potassium levels or hyperkalemia.

Hyperkalemia can cause irregular heartbeats, potentially leading to cardiac arrest. The FDA announced the recall last Monday, noting that Glenmark manufactured the capsules.

The recall for BluePoint was issued the next day. Despite the recall, both companies said they have not received any reports of hyperkalemia or serious adverse events related to these products.

READ NEXT: FDA Warns Bimbo Bakeries to Not Label Products with Allergens When They Contain None 

What To Do When You Possess the Recalled Capsules

These capsules are intended for patients with hypokalemia or a condition marked by low potassium levels. They are distributed in bottles of 100 and 500. The FDA has made the batch numbers for the recalled capsules available on its website.

The FDA advised consumers who have recalled capsules to consult their physician before they stop using them or if they experience any health problems related to taking them.

READ MORE: FDA Approval of First Menthol E-Cigarettes for Sale in US Draws Parental Criticism